Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma

BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can experience BCMA antigen loss leading to relapse, thus necessitating th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Dongpeng, Huang, Haiwen, Qin, Huimin, Tang, Koukou, Shi, Xiangru, Zhu, Tingting, Gao, Yuqing, Zhang, Ying, Tian, Xiaopeng, Fu, Jianhong, Qu, Weiwei, Cai, Weilan, Xu, Yang, Wu, Depei, Chu, Jianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282100/
https://www.ncbi.nlm.nih.gov/pubmed/37339964
http://dx.doi.org/10.1038/s41467-023-39395-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282100/
https://www.ncbi.nlm.nih.gov/pubmed/37339964
http://dx.doi.org/10.1038/s41467-023-39395-4

Ejemplares similares